<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="50">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05160493</url>
  </required_header>
  <id_info>
    <org_study_id>20211206</org_study_id>
    <nct_id>NCT05160493</nct_id>
  </id_info>
  <brief_title>The Effect of Esketamine Combined With Pregabalin on Chronic Postsurgical Pain in Patients After Craniotomy.</brief_title>
  <official_title>The Effect of Esketamine Combined With Pregabalin on Chronic Postsurgical Pain in Patients After Craniotomy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Tiantan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Tiantan Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic postsurgical pain (CPSP), which is one of the most common and serious long term&#xD;
      complication of surgery，occurs in approximately 10% of patients after a surgical procedure.&#xD;
      Craniotomy was previously considered to have less chronic pain than other surgical&#xD;
      procedures. Contrarily, studies have reported incidences of chronic headache varies for type&#xD;
      of craniotomy, ranging from 23% to 34% at three months and 12% to 16% at one year after&#xD;
      surgery. In addition，CPSP is associated with adverse events, including postoperative&#xD;
      morbidity, increased health-care costs, significant impaired on quality of life, prolonged&#xD;
      opioid use. Optimising perioperative pain management should reduce the incidence of CPSP; The&#xD;
      non-opioid analgesics, such as ketamine and pregabalin, have also been used as components of&#xD;
      multimodal anesthetic protocols. Postoperative pain scores and opioid use are significantly&#xD;
      reduced in thoracotomy surgical patients given ketamine and pregabalin compared to control&#xD;
      groups.however, there is currently a lack of evidence regarding which therapeutic options are&#xD;
      most effective in reducing the incidence of chronic post-craniotomy headache. The&#xD;
      investigators hypothesis is that sketamine combined with pregabalin reduces significantly&#xD;
      chronic postoperative pain after craniotomy and improves patient outcome.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 15, 2021</start_date>
  <completion_date type="Anticipated">March 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Parallel Assignment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of craniotomy patients with NRS score greater than one 3 months after surgery</measure>
    <time_frame>3 months after surgery</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">246</enrollment>
  <condition>Chronic Postsurgical Pain</condition>
  <arm_group>
    <arm_group_label>S-ketamine and pregabalin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: S-ketamine and pregabalin&#xD;
Drug: Pregabalin 150mg (2hrs) pre operatively and 75mg twice daily post operatively for 7 days(POD1-7),followed by dose reduction to 75mg once daily for 7days(POD8-14)&#xD;
Drug: S-ketamine infusion 0.5 mg/kg bolus after induction of anesthesia +0.12 mg/kg/h continuous intravenous infusion for 48 h</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal saline and placebo capsule</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Drug: Normal saline and placebo capsule&#xD;
Drug: Placebo capsules :Two placebo capsules(2hrs) preoperatively and twice daily post operatively for 7days, followed by dose reduction to single capsule once daily for 7days&#xD;
Drug: Normal saline• 0.9% saline bolus after induction of anesthesia +intravenous infusion for 48 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-ketamine and pregabalin</intervention_name>
    <description>S-ketamine and pregabalin&#xD;
Drug: Pregabalin • 150mg (2hrs) pre operatively and 75mg twice daily post operatively for 7 days(POD1-7),followed by dose reduction to 75mg once daily for 7days(POD8-14)&#xD;
Drug: S-ketamine infusion • 0.5 mg/kg bolus after induction of anesthesia +0.12 mg/kg/h continuous intravenous infusion for 48 h</description>
    <arm_group_label>S-ketamine and pregabalin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline and placebo capsule</intervention_name>
    <description>Normal saline and placebo capsule</description>
    <arm_group_label>Normal saline and placebo capsule</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults, age ≥18 years, male or female&#xD;
&#xD;
          -  American Society of Anaesthesiology (ASA) status I-III&#xD;
&#xD;
          -  Patients undergoing elective craniotomy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients unable to complete scale assessment&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Patients with preoperative chronic pain syndrome&#xD;
&#xD;
          -  Patients with previous craniotomy history&#xD;
&#xD;
          -  Patients with a history of mental illness who are receiving medication&#xD;
&#xD;
          -  Patients with liver and kidney dysfunction&#xD;
&#xD;
          -  Patients have taken pain medication within two weeks&#xD;
&#xD;
          -  Patients with history of adverse reactions to pregabalin, ketamine and esticketamine&#xD;
&#xD;
          -  Patients with history of drug abuse;&#xD;
&#xD;
          -  BMI&gt;35.0 kg · m - 2.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ruquan Han, M.D., Ph D.</last_name>
    <role>Study Chair</role>
    <affiliation>Beijing Tiantan Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ruquan Han, M.D., Ph D.</last_name>
    <phone>8610-59976660</phone>
    <email>ruquan.han@ccmu.edu.cn</email>
  </overall_contact>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>December 7, 2021</study_first_submitted>
  <study_first_submitted_qc>December 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2021</study_first_posted>
  <last_update_submitted>December 15, 2021</last_update_submitted>
  <last_update_submitted_qc>December 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Tiantan Hospital</investigator_affiliation>
    <investigator_full_name>Ruquan Han</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Esketamine</keyword>
  <keyword>Pregabalin</keyword>
  <keyword>Craniotomy</keyword>
  <keyword>Chronic Postsurgical Pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pregabalin</mesh_term>
    <mesh_term>Ketamine</mesh_term>
    <mesh_term>Esketamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

